We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu
Trial record 2 of 5 for:    asterias

Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

This study is currently recruiting participants.
Verified October 2017 by Asterias Biotherapeutics, Inc.
ClinicalTrials.gov Identifier:
First Posted: November 26, 2014
Last Update Posted: October 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Asterias Biotherapeutics, Inc.
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).

Condition Intervention Phase
Cervical Spinal Cord Injury Spine Injury Spinal Cord Trauma Biological: AST-OPC1 Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Resource links provided by NLM:

Further study details as provided by Asterias Biotherapeutics, Inc.:

Primary Outcome Measures:
  • Number of adverse events within 1 year (365 days) that are related to AST-OPC1 injection [ Time Frame: One Year ]

Secondary Outcome Measures:
  • Neurological function as measured by upper extremity motor scores and motor level on International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) examinations at 30, 60, 90, 180, 270, and 365 days after injection of AST-OPC1 [ Time Frame: One Year ]

Estimated Enrollment: 35
Study Start Date: March 2015
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AST-OPC1
Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point
Biological: AST-OPC1
One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Major Inclusion Criteria:

  • Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
  • Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
  • Last fully preserved single neurological level (SNL) from C-4 to C-7
  • From 18 through 69 years of age at time of injury
  • Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI) scan, with sufficient visualization of the spinal cord injury epicenter and lesion margins to enable post-injection safety monitoring
  • Informed consent for this protocol and the companion long term follow-up protocol must be provided and documented (i.e., signed informed consent forms) no later than 37 days following injury
  • Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days following SCI

Major Exclusion Criteria:

  • SCI due to penetrating trauma
  • Traumatic anatomical transection or laceration of the spinal cord based on prior surgery or MRI
  • Any concomitant injury that interferes with the performance, interpretation or validity of neurological examinations
  • Inability to communicate effectively with neurological examiner such that the validity of patient data could be compromised
  • Significant organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression
  • History of any malignancy (except non-melanoma skin cancers)
  • Pregnant or nursing women
  • Body mass index (BMI) > 35 or weight > 300 lbs.
  • Active participation in another experimental procedure/intervention
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02302157

United States, California
Univ. of California at San Diego Recruiting
La Jolla, California, United States, 92093
Contact: Teresa Rzesiewicz    844-317-7836    alphastemcellclinic@ucsd.edu   
Principal Investigator: Joseph Ciacci, MD         
Rancho Los Amigos/USC Recruiting
Los Angeles, California, United States
Contact: Sheetal Desai    562-401-7020    sheetald@ranchoresearch.org   
Contact: Sandra Oviedo    (323) 865-9873    sandra.oviedo@health.usc.edu   
Principal Investigator: Charles Liu, MD, PhD         
Stanford University/Santa Clara Valley Medical Center Recruiting
San Jose, California, United States, 95128
Contact: Nhung Quach    408-885-3962    Nhung.Quach@hhs.sccgov.org   
Contact: Maria Coburn    650-736-9551    cellsforSCI@stanford.edu   
Principal Investigator: Gary K Steinberg, MD         
Sub-Investigator: Stephen McKenna, MD         
United States, Georgia
Shepherd Center Recruiting
Atlanta, Georgia, United States, 30309
Contact: Admissions    800-743-7437    admissions@shepherd.org   
Principal Investigator: Donald P Leslie, MD         
United States, Illinois
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Mary Messenger    312-563-6827    Mary_Messenger@rush.edu   
Contact: Carol MacPherson       Carol_L_MacPherson@rush.edu   
Principal Investigator: Richard G Fessler, MD, PhD         
United States, Indiana
Indiana University Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Heather Cero    317-396-1298    hcero@goodmancampbell.com   
Principal Investigator: Eric M Horn, MD, PhD         
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63110
Contact: John Evans    314-362-3473    evansj@wudosis.wustl.edu   
Principal Investigator: Wilson Zack Ray, MD         
United States, Pennsylvania
Thomas Jefferson University/Magee Rehabilitation Active, not recruiting
Philadelphia, Pennsylvania, United States, 19107
United States, Wisconsin
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Charlotte Klis    414-805-7183    cklis@mcw.edu   
Principal Investigator: Kurpad Shekar, MD, PhD         
Sponsors and Collaborators
Asterias Biotherapeutics, Inc.
Study Director: Edward D Wirth III, MD, PhD Asterias Biotherapeutics
  More Information

Responsible Party: Asterias Biotherapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02302157     History of Changes
Other Study ID Numbers: AST-OPC1-01
First Submitted: November 24, 2014
First Posted: November 26, 2014
Last Update Posted: October 24, 2017
Last Verified: October 2017

Keywords provided by Asterias Biotherapeutics, Inc.:
Cervical spinal cord injury
Neural cell
Trauma spinal cord
stemcell transplant
Cervical spine injury
Spine injury
oligodendrocyte progenitor cell
Subacute spinal cord injury

Additional relevant MeSH terms:
Wounds and Injuries
Spinal Cord Injuries
Spinal Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Back Injuries